Product image of Medoclazide (Gliclazide) supplied by GNH India

Medoclazide

Active Ingredient:
Gliclazide
Origin:
EU

Medoclazide (Gliclazide)

Gliclazide, the active ingredient in Medoclazide, is a second‑generation sulfonylurea presented as an oral tablet for oral use. It is used to lower blood glucose in adults with type 2 diabetes mellitus by stimulating insulin release from pancreatic β‑cells and is typically prescribed when diet, exercise, and other oral agents are insufficient.

GNH India supplies Medoclazide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gliclazide is used in the management of hyperglycaemia associated with type 2 diabetes mellitus, either alone or in combination with lifestyle measures.

  • Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion from pancreatic β‑cells.
  • Adjunct to diet and exercise in type 2 diabetes: helps achieve target blood glucose when lifestyle measures are insufficient.
  • Monotherapy in newly diagnosed type 2 diabetes: provides initial glucose‑lowering effect as a first‑line oral agent.

How It Works

  • Gliclazide binds to the sulfonylurea receptor subunit (SUR1) of the ATP‑sensitive potassium channel on pancreatic β‑cells. This interaction closes the K‑ATP channel, causing membrane depolarisation, calcium influx and subsequent exocytosis of insulin granules, thereby increasing circulating insulin levels and lowering blood glucose. The drug does not directly affect insulin sensitivity and its effect is glucose‑dependent, diminishing as plasma glucose falls, which reduces the risk of severe hypoglycaemia compared with some older sulfonylureas.

Side Effects

Gliclazide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Hypoglycaemia: mild to moderate low blood glucose episodes, especially with missed meals.
  • Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea.
  • Dizziness or headache: transient sensations of light‑headedness or mild head pain.
  • Weight gain: modest increase in body weight due to enhanced insulin action.
  • Skin reactions: mild rash or pruritus.

Serious or Rare Side Effects

  • Severe hypoglycaemia: profound low glucose requiring assistance.
  • Hemolytic anaemia: rare destruction of red blood cells.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Allergic reactions: anaphylaxis or severe skin eruptions.

Precautions & Warnings

When prescribing gliclazide, clinicians should consider several precautionary measures to minimise risk and ensure safe use.

  • Renal impairment: dose adjustment or avoidance in severe kidney disease.
  • Hepatic dysfunction: use cautiously in patients with liver disease.
  • Elderly patients: start with lower dose and monitor for hypoglycaemia.
  • Concomitant sulfonylureas: avoid combining with other agents of the same class.
  • Pregnancy and lactation: classified as Category B; use only if benefit outweighs risk.
  • Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Avoid Interactions

Gliclazide can interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid)

  • Concurrent use of other sulfonylureas or meglitinides: additive hypoglycaemia risk.
  • Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase gliclazide plasma levels.
  • MAO‑B inhibitors: may potentiate hypoglycaemic effect.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask hypoglycaemia symptoms.
  • Thiazide diuretics: can enhance hyperglycaemic effect.
  • Anticoagulants (warfarin): gliclazide may affect INR, requiring monitoring.

Frequently Asked Questions

Medoclazide contains gliclazide, an oral antidiabetic medication indicated for the treatment of type 2 diabetes mellitus. It helps lower elevated blood glucose by stimulating insulin release from the pancreas, and is used when diet, exercise, or other oral agents alone do not achieve glycaemic targets.

Gliclazide binds to the sulfonylurea receptor (SUR1) on pancreatic β‑cell potassium channels, causing channel closure. This leads to cell depolarisation, calcium influx and the release of stored insulin, thereby increasing circulating insulin levels and reducing blood glucose concentrations.

The appropriate dose of Medoclazide is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, renal and hepatic function, and other relevant factors. No fixed dosing regimen is provided here.

Gliclazide is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no well‑controlled studies in pregnant women. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the Medoclazide product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Gliclazide is a second‑generation sulfonylurea that offers a lower risk of severe hypoglycaemia compared with first‑generation sulfonylureas. Unlike metformin, it does not improve insulin sensitivity, and unlike newer agents such as DPP‑4 inhibitors, it directly stimulates insulin release, which may be advantageous in patients with preserved β‑cell function.

Medoclazide tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Medoclazide is taken orally, usually with a meal to reduce the risk of hypoglycaemia. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include severe hypoglycaemia, which can be life‑threatening if not recognised and treated promptly, as well as rare events such as hemolytic anaemia, hepatotoxicity and severe allergic reactions including anaphylaxis. Patients should be educated on recognising early signs of low blood glucose.

Medoclazide should be avoided in patients with known hypersensitivity to gliclazide or other sulfonylureas, in individuals with severe renal or hepatic impairment, and in those who are pregnant or breastfeeding unless the benefit outweighs the risk. It is also contraindicated when used together with other sulfonylureas.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gliclazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT